NEW YORK, Oct. 15, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the third quarter ended September 30, 2020, and provided a corporate update.
"The most important near-term event for BrainStorm will be the upcoming top-line data readout for the NurOwn Phase 3 trial in ALS, expected by the end of November. A successful outcome will set us on the path to filing a Biologic License Application (BLA) for what we believe will be a valuable new treatment for ALS," said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. "In parallel to our preparations for upcoming data read out, we are very busy planning and executing on other pre-BLA activities. On the management front, we appointed William K. White and Dr. Anthony Waclawski, adding valuable commercial and regulatory expertise to our leadership team. This expertise will be crucial as we work towards obtaining regulatory approval for NurOwn and ensuring that, if approved, it will be readily accessible to ALS patients in need of new treatment options for this devastating disease."
NurOwn has an innovative mechanism of action that is broadly applicable across neurodegenerative diseases and BrainStorm continues to invest in clinical trials evaluating the product in conditions beyond ALS to maximize value creation for its various stakeholders. The company remains on track to complete dosing in its Phase 2 clinical trial in progressive multiple sclerosis (PMS) by the end of 2020. In addition, the Company recently unveiled a clinical development program in Alzheimer's' disease (AD) and is planning a Phase 2 proof-of-concept clinical trial at several leading AD centers in the Netherlands and France.
Third Quarter 2020 and Recent Corporate Highlights:
Presented at the following Investor Conferences:
Cash and Liquidity as of October 14, 2020
Total available funding as of October 14, 2020, which includes cash, cash equivalents and short-term bank deposits of approximately $33.1 million as well as remaining non-dilutive funding from CIRM, IIA and other grants, amounts to approximately $36 million.
Financial Results for the Three Months Ended September 30, 2020
Conference Call & WebcastThursday, October 15, 2020 at 8 a.m. Eastern TimeFrom the US:877-407-9205International: 201-689-8054Webcast:https://www.webcaster4.com/Webcast/Page/2354/37811
Replays, available through October 29, 2020From the US:877-481-4010International: 919-882-2331Replay Passcode: 37811
About NurOwn
NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and completed enrollment inAugust 2020.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment inAugust 2020. For more information, visit the company's website atwww.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
ContactsInvestor Relations:Corey Davis, Ph.D.LifeSci Advisors, LLCPhone: +1 646-465-1138[emailprotected]
Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768[emailprotected]
BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIESINTERIM CONDENSED CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)
September30,
December31,
2020
2019
U.S.$ inthousands
Unaudited
Audited
ASSETS
Current Assets:
Cash and cash equivalents
$
24,770
$
536
Short-term deposit (Note 4)
4,038
33
Other accounts receivable
1,473
2,359
Prepaid expenses and other current assets (Note 5)
56
432
Total current assets
30,337
3,360
Long-Term Assets:
Prepaid expenses and other long-term assets
27
32
Operating lease right of use asset (Note 6)
1,377
2,182
Property and Equipment, Net
950
960
Total Long-Term Assets
2,354
3,174
Total assets
$
32,691
$
6,534
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current Liabilities:
Accounts payable
$
3,283
$
14,677
Accrued expenses
917
1,000
Operating lease liability (Note 6)
1,216
1,263
Other accounts payable
1,013
714
Total current liabilities
6,429
17,654
Long-Term Liabilities:
Operating lease liability (Note 6)
284
1,103
Total long-term liabilities
284
1,103
Total liabilities
$
6,713
$
18,757
Stockholders' Equity (deficit):
Stock capital: (Note 7)
12
11
Common Stock of $0.00005 par value - Authorized: 100,000,000 shares at September 30, 2020 and December 31, 2019 respectively; Issued and outstanding: 31,567,592 and 23,174,228 shares at September 30,2020 and December31,2019 respectively.
Go here to read the rest:
- Senescent mesenchymal stem/stromal cells and restoring their cellular ... - January 13th, 2025
- Mesenchymal Stem Cells and Reticulated Platelets: New Horizons in ... - January 13th, 2025
- Mesenchymal Stem Cells/Medicinal Signaling Cells (MSCs) - GlobeNewswire - January 13th, 2025
- A SAGE View of Mesenchymal Stem Cells - PMC - January 13th, 2025
- Mesenchymal stem cell perspective: cell biology to clinical progress - January 3rd, 2025
- Canid alphaherpesvirus 1 infection alters the gene expression and secretome profile of canine adipose-derived mesenchymal stem cells in vitro -... - December 28th, 2024
- MSC-derived exosomal circMYO9B accelerates diabetic wound healing by promoting angiogenesis through the hnRNPU/CBL/KDM1A/VEGFA axis - Nature.com - December 27th, 2024
- Korean researchers prove stem cell therapys effectiveness for hereditary cerebellar ataxia in animal models - KBR - December 25th, 2024
- FDA Approves First MSC Therapy in Steroid-Refractory GVHD - www.oncnursingnews.com/ - December 25th, 2024
- FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid ... - December 22nd, 2024
- FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids - Medpage Today - December 20th, 2024
- FDA Grants First-Ever Approval for MSC Therapy to Australian Company Mesoblast After Attempting for 4 Years - geneonline - December 20th, 2024
- Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga - December 20th, 2024
- Mesoblast finally pushes GvHD cell therapy over finish line - pharmaphorum - December 20th, 2024
- Mesenchymal stem cells in health and disease - PubMed - December 19th, 2024
- Mesoblast's RYONCIL is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - The Manila Times - December 19th, 2024
- FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease - PR Newswire - December 19th, 2024
- RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch - December 17th, 2024
- An injury-induced mesenchymal-epithelial cell niche coordinates regenerative responses in the lung - Science - December 15th, 2024
- New insights into survival of breast cancer cells in the bone marrow - News-Medical.Net - December 9th, 2024
- Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidates (ERNA-101) Ability to Induce and Modulate... - December 7th, 2024
- Enhanced osteogenic potential of iPSC-derived mesenchymal progenitor cells following genome editing of GWAS variants in the RUNX1 gene - Nature.com - December 7th, 2024
- Exploring the potential of MSCs in cancer therapy - News-Medical.Net - December 5th, 2024
- Eterna Therapeutics Partners with MD Anderson to Advance Cancer Cell Therapy Research | ERNA Stock News - StockTitan - December 5th, 2024
- How breast cancer cells survive in bone marrow after remission - Medical Xpress - December 5th, 2024
- A blood glucose fluctuation-responsive delivery system promotes bone regeneration and the repair function of Smpd3-reprogrammed BMSC-derived exosomes... - December 1st, 2024
- Mesenchymal stromal cells alleviate depressive and anxiety-like ... - December 1st, 2024
- Human mesenchymal stem/stromal cell based-therapy in diabetes mellitus ... - December 1st, 2024
- Exploring mesenchymal stem cells homing mechanisms and ... - PubMed - November 26th, 2024
- Macrophage tracking with USPIO imaging and T2 mapping predicts immune rejection of transplanted stem cells - Nature.com - November 26th, 2024
- IL-10RA governor the expression of IDO in the instruction of lymphocyte immunity - Nature.com - November 26th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - November 26th, 2024
- Researchers have brought the promise of stem cell therapies closer to reality - The Week - November 25th, 2024
- Engineering bone/cartilage organoids: strategy, progress, and application - Nature.com - November 25th, 2024
- Proteomic analysis of human Whartons jelly mesenchymal stem/stromal cells and human amniotic epithelial stem cells: a comparison of therapeutic... - November 20th, 2024
- Clinical outcomes of autologous adipose-derived mesenchymal stem cell combined with high tibial osteotomy for knee osteoarthritis are correlated with... - November 20th, 2024
- Mesenchymal stem cells lineage and their role in disease development - November 18th, 2024
- Mesenchymal Stem Cells - SpringerLink - November 18th, 2024
- Exosomes: The Insulin of Our Era? - University of Miami - November 18th, 2024
- Partner Perspectives: Mesenchymal Stromal Cells Could Serve as Preventive Therapy for Chronic Radiation-Induced Dry Mouth - OncLive - November 10th, 2024
- Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' - Glossy - November 8th, 2024
- Substantial Overview on Mesenchymal Stem Cell Biological and Physical ... - November 8th, 2024
- Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23 - Newswire - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - StockTitan - November 8th, 2024
- Stem cell science is dominating the luxury skin-care market as human-derived ingredients become less taboo - Glossy - November 8th, 2024
- BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health - The Manila Times - November 8th, 2024
- SMART researchers develop a method to enhance effectiveness of cartilage repair therapy - MIT News - October 25th, 2024
- Biological functions of mesenchymal stem cells and clinical ... - October 24th, 2024
- Chemical-defined medium supporting the expansion of human mesenchymal ... - October 24th, 2024
- Mesenchymal Stem Cells: Time to Change the Name! - PMC - October 24th, 2024
- Insights into the molecular characteristics of embryonic cranial neural crest cells and their derived mesenchymal cell pools - Nature.com - October 20th, 2024
- Acquisition of durable insulin-producing cells from human adipose tissue-derived mesenchymal stem cells as a foundation for cell- based therapy of... - October 20th, 2024
- Sources and Clinical Applications of Mesenchymal Stem Cells - October 20th, 2024
- Effects of inorganic phosphate on stem cells isolated from human exfoliated deciduous teeth - Nature.com - October 18th, 2024
- Researchers pioneer novel method to enhance effectiveness of MSC therapy for cartilage repair - Medical Xpress - October 18th, 2024
- Healing begins with research: Promising development program on stem cells in rare diseases - Yahoo! Voices - October 15th, 2024
- Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles - Nature.com - October 15th, 2024
- Manufactured stem cells could help to treat blood cancers in the future - Health Tech World - October 14th, 2024
- miR-16a-5p antagonizes FGF-2 in ligamentogenic differentiation of MSC: a new therapeutic perspective for tendon regeneration - Nature.com - October 11th, 2024
- Effects, methods and limits of the cryopreservation on mesenchymal stem ... - October 10th, 2024
- ALKBH5 regulates etoposide-induced cellular senescence and osteogenic differentiation in osteoporosis through mediating the m6A modification of VDAC3... - October 10th, 2024
- Mesenchymal stromal cells: Biology of adult mesenchymal stem cells ... - October 8th, 2024
- Clever Robotic clothing and manufactured stem cells to treat cancer among revolutionary healthcare tech projects - University of Strathclyde - October 8th, 2024
- Dr. Peisong Gao, MD, PhD - Hopkins Medicine - October 4th, 2024
- Research to Boost Bone Formation Informs Orthopaedic Treatments - October 4th, 2024
- Garza Laboratory - Johns Hopkins Medicine - October 4th, 2024
- Stem Cell Treatment Promises to Prevent Disease and Slow Aging - Newsweek - September 30th, 2024
- Survival advantage of native and engineered T cells is acquired by mitochondrial transfer from mesenchymal stem cells - Journal of Translational... - September 28th, 2024
- A mathematical insight to control the disease psoriasis using mesenchymal stem cell transplantation with a biologic inhibitor - Nature.com - September 20th, 2024
- Mesenchymal stem cells in tumor microenvironment: drivers of bladder cancer progression through mitochondrial dynamics and energy production -... - September 20th, 2024
- Implication of CXCR2-Src axis in the angiogenic and osteogenic effects of FP-TEB - Nature.com - September 20th, 2024
- Strategic targeting of miR-183 and -catenin to enhance BMSC stemness in age-related osteoporosis therapy - Nature.com - September 16th, 2024
- The order of green and red LEDs irradiation affects the neural differentiation of human umbilical cord matrix-derived mesenchymal cells - Nature.com - September 14th, 2024
- ENCell and Lucy Biotech Sign a Strategic Alliance and Licensing Agreement for the Next generation Mesenchymal Stem Cell Therapy (EN001) - PR Newswire - September 14th, 2024
- Japanese brand Eternam taps regenerative medicine to develop lip and skin care from umbilical cord-derived stem cell - CosmeticsDesign-Asia.com - September 10th, 2024
- Advances in Tissue Engineering and Its Future in Regenerative Medicine Compared to Traditional Reconstructive Techniques: A Comparative Analysis -... - September 8th, 2024
- Editorial: The future direction toward immunological issues of allo-and xeno-islet transplantation - Frontiers - September 8th, 2024
- Translational potential of mesenchymal stem cells in regenerative ... - September 4th, 2024
- Global microRNA profiling of bone marrow-MSC derived extracellular vesicles identifies miRNAs associated with hematopoietic dysfunction in aplastic... - August 24th, 2024
- A Comprehensive Review of the Role of Stem Cells in Neuroregeneration: Potential Therapies for Neurological Disorders - Cureus - August 22nd, 2024
Recent Comments